Adding Pembrolizumab to Chemotherapy Results in Improved PFS and OS in Patients with Advanced and Recurrent Cervical Cancer Regardless of Bevacizumab Use By Ogkologos - November 25, 2024 209 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the subgroup analysis of the KEYNOTE-826 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer EMA Recommends Extension of Indications for Cabozantinib MOST POPULAR Patient Exposure to Anticancer Drugs Subsequently Withdrawn from the FDA Accelerated... March 9, 2023 FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute... October 7, 2021 Cancer-Related Fatigue: What People With Cancer and Their Loved Ones Should... August 18, 2020 Neoadjuvant Nivolumab/Relatlimab Induces High Rates of Pathologic Responses in Patients with... November 22, 2024 Load more HOT NEWS This Program Provides Free Mammograms And Breast Cancer Treatment Services To... When Ovarian Cancer Returns, Surgery May Be a Good Choice for... COVID-19: “We’ve got so much on our plates” Doctors Want Breast Cancer Warning Label Put On Cheese